Oral Semaglutide Demonstrates Real-World Efficacy and Safety for Diabetes and Obesity Management

Type 2 diabetes (T2D) and obesity are global health crises, often co-occurring and driving significant morbidity and mortality. Current treatments for T2D and obesity include highly effective injectable GLP-1 receptor agonists, but adherence can be challenging due to injection burden. Oral formulations offer a significant advantage in convenience, potentially improving long-term adherence and broader patient access. Oral semaglutide, a GLP-1 receptor agonist, was developed to address this gap, providing a non-injectable option for chronic management. This meta-analysis consolidates real-world data to assess its performance outside of controlled clinical trials.

This study conducted a comprehensive meta-analysis of real-world evidence to evaluate the efficacy and safety of oral semaglutide. Researchers systematically reviewed and synthesized data from various real-world settings, including observational studies, registries, and electronic health records. The analysis focused on adults with type 2 diabetes and/or obesity receiving oral semaglutide. Primary endpoints included changes in HbA1c, body weight, and various safety outcomes. The methodology involved pooling data from diverse populations to provide a robust overview of oral semaglutide's performance in routine clinical practice.